Medpace Holdings, Inc.(MEDP)Earnings, Financials & Key RatiosMedpace Holdings, Inc. (MEDP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company exhibits strong fundamental momentum with a 26.5% revenue growth rate and a robust FCF margin of 21.5% in 2026Q1, justifying its current valuation despite sector-specific funding risks.
Medpace Holdings, Inc. (MEDP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Medpace Holdings, Inc. (MEDP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 22, 2026 | $4.28vs $3.92+9.2% | $707Mvs $698M+1.3% |
| Q1 2026 | Feb 9, 2026 | $4.67vs $4.19+11.5% | $708Mvs $689M+2.8% |
| Q4 2025 | Oct 22, 2025 | $3.86vs $3.53+9.3% | $660Mvs $641M+2.9% |
| Q3 2025 | Jul 21, 2025 | $3.10vs $2.98+4.0% | $603Mvs $539M+12.0% |
Recent stock market news and headlines for Medpace Holdings, Inc. (MEDP)
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.
Key metrics vs top competitors for Medpace Holdings, Inc. (MEDP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $546.29 | $15.6B | 35.75 | 19.97% | 17.83% | 70.23% | — | |
| $168.72 | $12.92B | 58.18 | -0.37% | 5.35% | 4.7% | — | |
| $228.68 | $11.01B | -78.58 | -0.85% | -4.59% | -5.66% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $36.17 | $7.94B | 70.92 | 59% | -0.56% | -2.48% | — | |
| $208.23 | $35.34B | 26.56 | 5.87% | 8.33% | 22.11% | — |
Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 22, 2026·SEC
Feb 9, 2026·SEC
Oct 22, 2025·SEC
Get notified when MEDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained
Medpace Holdings, Inc. (MEDP) reported $2.68B in revenue for fiscal year 2025. This represents a 823% increase from $290.0M in 2014.
Medpace Holdings, Inc. (MEDP) grew revenue by 20.0% over the past year. This is strong growth.
Yes, Medpace Holdings, Inc. (MEDP) is profitable, generating $460.4M in net income for fiscal year 2025 (17.8% net margin).
Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This is excellent, indicating efficient use of shareholder capital.
Medpace Holdings, Inc. (MEDP) generated $744.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
